Chen, L., & Han, X. (2015). Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation, 125(9), 3384–3391. https://doi.org/10.1172/JCI80011

Article  PubMed  PubMed Central  Google Scholar 

Pauken, K. E., & Wherry, E. J. (2015). Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 36(4), 265–276. https://doi.org/10.1016/j.it.2015.02.008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J. (2022). Programmed death ligand 1 signals in cancer cells. Nature Reviews. Cancer, 22(3), 174–189. https://doi.org/10.1038/s41568-021-00431-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanks, B. A. (2022). The “Inside” Story on Tumor-Expressed PD-L1. Cancer Research, 82(11), 2069–2071. https://doi.org/10.1158/0008-5472.CAN-22-1060

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kornepati, A. V. R., Boyd, J. T., Murray, C. E., Saifetiarova, J., de la Peña Avalos, B., Rogers, C. M., et al. (2022). Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Cancer Research, 82(11), 2156–2170. https://doi.org/10.1158/0008-5472.CAN-21-2076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., et al. (2019). PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell, 74(6), 1215–1226.e4. https://doi.org/10.1016/j.molcel.2019.04.005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark, C. A., Gupta, H. B., Sareddy, G., Pandeswara, S., Lao, S., Yuan, B., et al. (2016). Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Research, 76(23), 6964–6974. https://doi.org/10.1158/0008-5472.CAN-16-0258

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., et al. (2015). Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell, 162(6), 1229–1241. https://doi.org/10.1016/j.cell.2015.08.016

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., et al. (2015). Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Molecular Cancer, 14, 149. https://doi.org/10.1186/s12943-015-0421-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, C., Li, S., Xue, J., Qi, M., Liu, X., Huang, Y., et al. (2021). PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight, 6(8), 131458. https://doi.org/10.1172/jci.insight.131458

Article  PubMed  Google Scholar 

Nieto, C., Miller, B., Alzofon, N., Chimed, T., Himes, J., Joshi, M., et al. (2023). The PD-L1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in HNSCC. Journal of the National Cancer Institute, djad126. https://doi.org/10.1093/jnci/djad126

Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., et al. (2019). Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine, 25(2), 301–311. https://doi.org/10.1038/s41591-018-0321-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., et al. (2014). Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 5, 5241. https://doi.org/10.1038/ncomms6241

Article  CAS  PubMed  Google Scholar 

Xie, M., Lin, Z., Ji, X., Luo, X., Zhang, Z., Sun, M., et al. (2023). FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Journal of Hepatology, 79(1), 109–125. https://doi.org/10.1016/j.jhep.2023.02.036

Article  CAS  PubMed  Google Scholar 

Ghosh, S., Nataraj, N. B., Noronha, A., Patkar, S., Sekar, A., Mukherjee, S., et al. (2021). PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Reports, 35(8), 109181. https://doi.org/10.1016/j.celrep.2021.109181

Article  CAS  PubMed  Google Scholar 

Jiang, Y., & Zhan, H. (2020). Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Letters, 468, 72–81. https://doi.org/10.1016/j.canlet.2019.10.013

Article  CAS  PubMed  Google Scholar 

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., et al. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 381(16), 1535–1546. https://doi.org/10.1056/NEJMoa1910836

Article  CAS  PubMed  Google Scholar 

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020). Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/NEJMoa1910549

Article  CAS  PubMed  Google Scholar 

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., et al. (2018). Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medicine, 378(21), 1976–1986. https://doi.org/10.1056/NEJMoa1716078

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., et al. (2018). Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA oncology, 4(6), e180071. https://doi.org/10.1001/jamaoncol.2018.0071

Article  PubMed  PubMed Central  Google Scholar 

Eggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., et al. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology, 22(5), 643–654. https://doi.org/10.1016/S1470-2045(21)00065-6

Article  CAS  PubMed  Google Scholar 

Gerstberger, S., Jiang, Q., & Ganesh, K. (2023). Metastasis. Cell, 186(8), 1564–1579. https://doi.org/10.1016/j.cell.2023.03.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou, Y., Hu, X., Zheng, S., Yang, A., Li, X., Tang, H., et al. (2021). Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. EBioMedicine, 63, 103137. https://doi.org/10.1016/j.ebiom.2020.103137

Article  CAS  PubMed  Google Scholar 

Torborg, S. R., Li, Z., Chan, J. E., & Tammela, T. (2022). Cellular and molecular mechanisms of plasticity in cancer. Trends in Cancer, 8(9), 735–746. https://doi.org/10.1016/j.trecan.2022.04.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez-González, A., Bévant, K., & Blanpain, C. (2023). Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nature Cancer, 4(8), 1063–1082. https://doi.org/10.1038/s43018-023-00595-y

Article  PubMed  PubMed Central  Google Scholar 

Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular Plasticity in Cancer. Cancer Discovery, 9(7), 837–851. https://doi.org/10.1158/2159-8290.CD-19-0015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059

Article  CAS  PubMed  Google Scholar 

Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews. Clinical Oncology, 14(10), 611–629. https://doi.org/10.1038/nrclinonc.2017.44

Article  PubMed  PubMed Central  Google Scholar 

Del Pozo Martin, Y., Park, D., Ramachandran, A., Ombrato, L., Calvo, F., Chakravarty, P., et al. (2015). Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization. Cell Reports, 13(11), 2456–2469. https://doi.org/10.1016/j.celrep.2015.11.025

Article  CAS  PubMed  Google Scholar 

Liu, M., Wang, R., Sun, X., Liu, Y., Wang, Z., Yan, J., et al. (2020). Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Molecular Oncology, 14(4), 865–881. https://doi.org/10.1002/1878-0261.12643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, S., Koh, J., Kim, M.-Y., Kwon, D., Go, H., Kim, Y. A., et al. (2016). PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology, 58, 7–14. https://doi.org/10.1016/j.humpath.2016.07.007

Article  CAS  PubMed